Krystal Biotech Management
Management criteria checks 4/4
Krystal Biotech's CEO is Krish Krishnan, appointed in Dec 2015, has a tenure of 8.92 years. total yearly compensation is $6.22M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 5.43% of the company’s shares, worth $292.49M. The average tenure of the management team and the board of directors is 2.8 years and 6.4 years respectively.
Key information
Krish Krishnan
Chief executive officer
US$6.2m
Total compensation
| CEO salary percentage | 11.8% |
| CEO tenure | 8.9yrs |
| CEO ownership | 5.4% |
| Management average tenure | 2.8yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$52m |
| Jun 30 2024 | n/a | n/a | US$106m |
| Mar 31 2024 | n/a | n/a | US$57m |
| Dec 31 2023 | US$6m | US$733k | US$11m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$3m | US$645k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$130m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$104m |
| Dec 31 2021 | US$7m | US$581k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$58m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$764k | US$498k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$631k | US$366k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$13m |
| Dec 31 2018 | US$705k | US$200k | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$69k | US$69k | -US$8m |
Compensation vs Market: Krish's total compensation ($USD6.22M) is about average for companies of similar size in the US market ($USD7.84M).
Compensation vs Earnings: Krish's compensation has been consistent with company performance over the past year.
CEO
Krish Krishnan (59 yo)
8.9yrs
Tenure
US$6,223,894
Compensation
Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since December 2015. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. K...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.9yrs | US$6.22m | 5.43% $ 292.5m | |
| Founder | 8.9yrs | US$3.84m | 5.53% $ 297.8m | |
| Executive VP & Chief Accounting Officer | 4.8yrs | US$2.57m | 0.045% $ 2.4m | |
| General Counsel & Corporate Secretary | no data | no data | no data | |
| Vice President of North American Sales & Marketing | no data | no data | no data | |
| Head of U.S. Sales & Marketing | less than a year | no data | no data | |
| Vice President of Corporate Development | no data | no data | no data | |
| Director of Human Resources & Operations | no data | no data | no data | |
| Senior VP & GM of Europe | no data | no data | no data | |
| Senior Vice President of Clinical Development | 2.8yrs | no data | no data | |
| Senior Vice President of Patient Access | less than a year | no data | no data | |
| Senior Vice President of Global Value and Access | less than a year | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Management: KRYS's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.9yrs | US$6.22m | 5.43% $ 292.5m | |
| Founder | 8.8yrs | US$3.84m | 5.53% $ 297.8m | |
| Lead Independent Director | 8yrs | US$610.32k | 0.37% $ 20.1m | |
| Independent Director | 7.4yrs | US$584.82k | 0.27% $ 14.7m | |
| Independent Director | 5.7yrs | US$585.07k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$570.44k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$568.32k | 0% $ 0 | |
| Non-Employee Independent Director | 7.2yrs | no data | no data | |
| Independent Director | 1.7yrs | US$934.43k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 4.8yrs | no data | no data |
6.4yrs
Average Tenure
59yo
Average Age
Experienced Board: KRYS's board of directors are considered experienced (6.4 years average tenure).